Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan

Leukemia volume 21, pages 1570–1571 (2007)Cite this article

The JAK2V617F mutation is an activating kinase that is constitutively expressed in the vast majority of patients with polycythemia vera and approximately half of those with essential thrombocythemia (ET).1 The significance of the association between JAK2V617F mutation in ET and thrombosis is still controversial: we have shown that ET patients with JAK2V617F had more frequent thrombotic episodes compared with those with wild-type JAK2, whereas the platelet count at the initial ET diagnosis did not differ between wild-type ET and JAK2V617F-positive ET.2 On the basis of this evidence, we retrospectively sought and evaluated thrombotic episodes in ET patients to obtain more insight into the risk factors of thrombosis in ET patients.

We used the JAK2 mutational status database in 49 patients with ET in our institute. The JAK2V617F mutation was determined using by the semiquantitative sequence-specific primer single-molecule fluorescence detection (SSP-SMPD) assay. As reported previously, ET patients with JAK2V617F showed a significantly higher incidence of thrombotic episodes (10/31 versus 1/18: P=0.0308), high leukocyte count (P=0.0092) and hemoglobin level (P=0.0044) than those with wild-type JAK2.2 ET patients with thrombosis had higher hemoglobin (14.5±1.5 versus 13.3±1.5 g/dl: P=0.0283) at initial diagnosis, whereas no significant differences were noted in leukocyte count (P=0.140), hematocrit level (P=0.0801) or platelet count (P=0.0877) (Supplementary Information 1). Of the ET patients with JAK2V617F mutation (n=31), no significant differences were noted in hematologic parameters regardless of whether they developed thrombosis or not.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.

    Article  CAS  PubMed  Google Scholar 

  2. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH . JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007, doi:10.1038/sj.leu.2404604.

    Article  CAS  PubMed  Google Scholar 

  3. Harrison CN . Platelet and thrombosis in myeloproliferative diseases. Hematology 2005, American Society of Hematology, Education Program Book 2005, 409–415.

    Article  Google Scholar 

  4. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1879.

    Article  CAS  PubMed  Google Scholar 

  5. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213.

    Article  CAS  PubMed  Google Scholar 

  6. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C . The presence of the JAK2 V617F mutation is associated with a higher hemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2005; 132: 244–250.

    Article  Google Scholar 

  7. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T . Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.

    Article  PubMed  Google Scholar 

  8. Carobbio A, Finazzi G, Guerini V, Spinelli O, Federica S, Delaini F et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007; 109: 2310–2313.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Professor JP Barron for his review of this manuscript. This work was supported in part by the ‘High-Tech Research Center’ Project from the Ministry of Education, Culture, Sports and Technology (MEXT) and by the ‘University-Industry Joint Research Project’ from MEXT.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine (Hematology Division), Tokyo Medical University, Tokyo, Japan

    K Ohyashiki & Y Ito

  2. NovusGene, Tokyo, Japan

    K Hori, K Sato & T Makino

  3. Intractable Immune System Diseases Research Center, Tokyo Medical University, Tokyo, Japan

    J H Ohyashiki

Authors
  1. K Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J H Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Ohyashiki.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohyashiki, K., Ito, Y., Hori, K. et al. Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan. Leukemia 21, 1570–1571 (2007). https://doi.org/10.1038/sj.leu.2404666

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404666

This article is cited by

Search

Advanced search

Quick links